Your browser doesn't support javascript.
loading
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Kumar, Shaji K; Harrison, Simon J; Cavo, Michele; de la Rubia, Javier; Popat, Rakesh; Gasparetto, Cristina; Hungria, Vania; Salwender, Hans; Suzuki, Kenshi; Kim, Inho; Punnoose, Elizabeth A; Hong, Wan-Jen; Freise, Kevin J; Yang, Xiaoqing; Sood, Anjla; Jalaluddin, Muhammad; Ross, Jeremy A; Ward, James E; Maciag, Paulo C; Moreau, Philippe.
Afiliación
  • Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: kumar.shaji@mayo.edu.
  • Harrison SJ; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Cavo M; Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
  • de la Rubia J; Hematology Service, Dr Peset University Hospital, Valencia, Spain; School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain.
  • Popat R; Department of Haematology, University College London Hospitals, London, UK.
  • Gasparetto C; School of Medicine, Duke University, Durham, NC, USA.
  • Hungria V; Clinica São Germano, São Paulo, Brazil.
  • Salwender H; Department of Hematology-Oncology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona and Asklepios Klinik St Georg, Hamburg, Germany.
  • Suzuki K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Kim I; Department of Rehabilitation Medicine, Seoul National University, Seoul, South Korea.
  • Punnoose EA; Oncology Biomarker Development, Product Development, Hemtology, Genentech, South San Francisco, CA, USA.
  • Hong WJ; Oncology Biomarker Development, Product Development, Hemtology, Genentech, South San Francisco, CA, USA.
  • Freise KJ; Research and Development, AbbVie, North Chicago, IL, USA.
  • Yang X; Research and Development, AbbVie, North Chicago, IL, USA.
  • Sood A; Research and Development, AbbVie, North Chicago, IL, USA.
  • Jalaluddin M; Research and Development, AbbVie, North Chicago, IL, USA.
  • Ross JA; Research and Development, AbbVie, North Chicago, IL, USA.
  • Ward JE; Research and Development, AbbVie, North Chicago, IL, USA.
  • Maciag PC; Research and Development, AbbVie, North Chicago, IL, USA.
  • Moreau P; Department of Hematology, University Hospital, Nantes, France.
Lancet Oncol ; 21(12): 1630-1642, 2020 12.
Article en En | MEDLINE | ID: mdl-33129376
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Compuestos Bicíclicos Heterocíclicos con Puentes / Inhibidores de Proteasoma / Bortezomib / Mieloma Múltiple Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Compuestos Bicíclicos Heterocíclicos con Puentes / Inhibidores de Proteasoma / Bortezomib / Mieloma Múltiple Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article